| Literature DB >> 30092151 |
András Inotai1,2, Huong Thanh Nguyen3, Budi Hidayat4, Talgat Nurgozhin5, Pham Huy Tuan Kiet6, Jonathan D Campbell7, Bertalan Németh1, Nikos Maniadakis8, Diana Brixner9, Kalman Wijaya10, Zoltán Kaló1,2.
Abstract
INTRODUCTION: Multiple Criteria Decision Analysis (MCDA) is increasingly used in health care mainly because it moves decision-making from ad hoc to an evidence-based and comprehensive process. Developing countries with more restricted financial and human research capacities, however, should consider their own methods of MCDA development and implementation. Areas covered: An MCDA framework to improve procurement decisions of off-patent pharmaceuticals was developed for developing countries and adapted to Indonesia, Kazakhstan and Vietnam during three policy workshops. Based on the experience of these workshops and one joint workshop with international experts and decision makers from multiple developing countries, general recommendations were formulated on how to implement MCDA specifically in developing countries. We provide 17 practical MCDA implementation recommendations in four major areas, including (1) MCDA objectives; (2) technical considerations of MCDA tool; (3) development and customization of MCDA tool and (4) policy implementation of MCDA in decision-making. Expert commentary: These practical MCDA recommendations for developing countries contribute to feasible, transparent, stepwise, iterative and standardized decision-making in health care.Entities:
Keywords: Decision Making; Developing Countries; Implementation Guidance; Multiple Criteria Decision Analysis; Off-patent Pharmaceuticals
Mesh:
Substances:
Year: 2018 PMID: 30092151 DOI: 10.1080/14737167.2018.1508345
Source DB: PubMed Journal: Expert Rev Pharmacoecon Outcomes Res ISSN: 1473-7167 Impact factor: 2.217